【摘要】 目的探讨急性冠脉综合征(ACS)患者C反应蛋白(CRP)和白介素6(IL6)的变化及辛伐他汀、依那普利对其的影响。方法对急性冠脉综合征患者83例和对照组130例检测血清CRP和IL6及对83例急性冠脉综合征患者进行联合辛伐他汀和依那普利的干预,探讨ACS患者CRP和IL6的变化及辛伐他汀和依那普利对其影响。结果①治疗前ACS组的CRP和IL6分别为16.08±1.22mg/L和30.21±8.34μg/L,与对照组比较P<0.01,②ACS组经4周辛伐他汀联合依那普利治疗后CRP和IL6分别为8.33±1.21mg/L和16.11±4.67μg/L,与治疗前比较P<0.01。结论ACS患者CRP和IL6水平均有明显升高,存在明显的炎症反应。辛伐他汀联合依那普利治疗能有效抑制此类炎症反应。更多还原

【Abstract】 AIM: To observe the influence of intervention with simvastatin and enalapril on the levels of C-reactive protein(CRP) and interleukin-6(IL-6) in patients with acute coronary syndrome(ACS). METHODS: The levels of serum CRP, IL-6 were detected respectively in 83 cases of ACS ,130 of matched controls. 83 cases of ACS received simvastatin and enalapril therapy to observe the influence of intervention with simvastatin and enalapril on the levels of CRP and IL-6 in patients with ACS. RESULTS: ①The levels of CRP, IL-6 were significantly higher in patients with ACS than in controls (16.08±1.22 mg/L vs 4.13±0.76 mg/L,P<0.01;30.21±8.34 μg/L vs 11.25±4.54 μg/L,P<0.01) respectively. ②After treatment with simvastatin and enalapril for 4 weeks, the levels of CRP,IL-6 in 83 patients with ACS decreased significantly(16.08±1.22 mg/L vs 8.33±1.21 mg/L,P<0.01, 30.21±8.34 μg/L vs 16.11±4.67 g/L,P<0.01) . CONCLUSION: The levels of CRP, IL-6 increased significantly in patients with ACS.Inflammation may play an important role in the ACS. Treatment with simvastatin and enalapril can inhibit the reaction of inflammation in patients with ACS and play a role in anti-atherosclerosis.更多还原